Morton Dl

1.5k citations
47 papers · 1.2k · 1 hit paper · h-index 16

Impact in

  • Oncology top 5%
    • Cutaneous Melanoma Detection and Management
    • Cancer Immunotherapy and Biomarkers
    • CAR-T cell therapy research
  • Immunology top 5%
    • Immunotherapy and Immune Responses
    • Immune Cell Function and Interaction

Papers in

    • Cutaneous Melanoma Detection and Management 7
    • Cancer Immunotherapy and Biomarkers 6
    • Immunotherapy and Immune Responses 19
    • Immune Cell Function and Interaction 3

Morton Dl

47 papers receiving 1.0k citations

Morton Dl's Hit Papers

Demonstration of antibodies against human malignant melanoma by immunofluorescence. 1968 · 320 citations
3200+19+38Years since publication100200300

Peers

Morton Dl
Comparison fields: 5 of 86
  • Oncology 634
  • Immunology 478
  • Radiology, Nuclear Medicine and Imaging 171
  • Dermatology 67
  • Immunology and Allergy 42
Replace Mark Egan with:
Mark Egan United Kingdom
G. J. Fleuren Netherlands
Holmes Ec United States
E. Douglas Holyoke United States
Maury Rosenstein United States
Paul Hobby United Kingdom
Frederick R. Aronson United States
Juan J. Roman United States
Boris Kubuschok Germany
F Squartini Italy
Morton Dl relative to Mark Egan United Kingdom Mark Egan's profile →
Citations per field
00.5×3.0×
Mark Egan · 1×
Citations per year

Countries citing papers authored by Morton Dl

Since Specialization
Citations

This map shows the geographic impact of Morton Dl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Morton Dl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Morton Dl more than expected).

Fields of papers citing papers by Morton Dl

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Morton Dl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Morton Dl. The network helps show where Morton Dl may publish in the future.

Co-authors

The 24 scholars most cited alongside Morton Dl, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Morton Dl Line = papers co-authored together Morton Dl links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 47 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Demonstration of antibodies against human malignant melanoma by immunofluorescence.
Hit paper breakdown →
1968320
2
Universal application of intraoperative lymphatic mapping and sentinel lymphadenectomy in solid neoplasms.
1999148
3
The determination of lymph shed by colloidal gold scanning in patients with malignant melanoma: a preliminary study.
1978102
4
Immunologic and virus studies with human sarcomas.
196978
5
Production of melanoma-associated antigen(s) by a defined malignant melanoma cell strain grown in chemically defined medium.
197661
6
Human leukocyte (alpha) interferon in metastatic malignant melanoma: the American Cancer Society phase II trial.
198447
7
Lymphatic mapping and sentinel lymphadenectomy for melanoma: past, present, and future.
200141
8
Intraoperative lymphatic mapping and sentinel lymphadenectomy: community standard care or clinical investigation?
199841
9
Immunosuppression by melanoma cells as a factor in the generation of metastatic disease.
198939
10
High-grade soft-tissue sarcomas of the extremity: UCLA experience with limb salvage.
198531
11
Vaccine therapy for patients with melanoma.
199930
12
Cancer immunotherapy: an overview.
197425
13
Horizons in tumor immunology.
197321
14
CCNU nephrotoxicity following sustained remission in oat cell carcinoma.
197919
15
Immunotherapy of human melanomas and sarcomas.
197216
16
Immunologic aspects of unknown primary melanoma.
198016
17
Humoral immune response to intralymphatic immunotherapy for disseminated melanoma: correlation with clinical response.
198215
18
Demonstration of lymphocyte blastogenesis--inhibiting factors in sera of melanoma patients.
197714
19
Immune response to postsurgical adjuvant active immunotherapy with Canvaxin polyvalent cancer vaccine: correlations with clinical course of patients with metastatic melanoma.
200412
20
Hybridoma monoclonal antibody: use in defining surface antigens on human lung carcinoma cells.
198111

About Morton Dl

Morton Dl is a scholar working on Oncology, Immunology, Molecular Biology, Radiology, Nuclear Medicine and Imaging and Surgery, having authored 47 papers that have together received 1.2k indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (19 papers), Cutaneous Melanoma Detection and Management (7 papers), Monoclonal and Polyclonal Antibodies Research (7 papers), Cancer Immunotherapy and Biomarkers (6 papers), Virus-based gene therapy research (4 papers), Glycosylation and Glycoproteins Research (3 papers), RNA Interference and Gene Delivery (3 papers) and Immune Cell Function and Interaction (3 papers). The work is most often cited by research in Oncology (634 citations), Immunology (478 citations), Radiology, Nuclear Medicine and Imaging (171 citations), Dermatology (67 citations) and Immunology and Allergy (42 citations). Morton Dl has collaborated with scholars based in United States. Frequent co-authors include Holmes Ec, Malmgren Ra, Ketcham As, G. Schidlovsky, Richard Essner, Pond R. Kelemen, Stuart Sostrin, A E Giuliano, Peter J. Bostick and Roth Ja. Their work appears in journals such as American Journal of Roentgenology, International Journal of Oncology and PubMed.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact